Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
Evaluate the safety and efficacy of Inaticabtagene autoleucel combined with autologous hematopoietic stem cell transplantation in adolescents or adults with MRD-positive initial complete remission in B-cell acute lymphoblastic leukemia.
B-cell Acute Lymphoblastic Leukemia
BIOLOGICAL: Inaticabtagene autoleucel
Relapse-Free Survival, The time from the start of infusion of Inaticabtagene autoleucel until the diagnosis of relapse or any death (whichever comes first)., From autologous hematopoietic stem cell transplantation to 2 years after transplantation
Overall survival rate, From autologous hematopoietic stem cell transplantation to 2 years after transplantation|Cumulative recurrence rate, From autologous hematopoietic stem cell transplantation to 2 years after transplantation|MRD negativity rate, 28 days after the first CAR-T cell reinfusion
Evaluate the safety and efficacy of Inaticabtagene autoleucel combined with autologous hematopoietic stem cell transplantation in adolescents or adults with MRD-positive initial complete remission in B-cell acute lymphoblastic leukemia.